{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-271921","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.828817+00:00","generated_at":"2026-06-08T17:06:36.923608+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sensei Biotherapeutics Q3 net loss $7.1M; cash $72M; SNS-101 Phase 1 data positive","bullets":["Net loss $7.1M in Q3 2023 vs $13.4M in Q3 2022; cash $72.0M as of Sept 30, 2023, down from $107.1M at Dec 31, 2022.","R&D expenses $3.8M vs $9.2M YoY; G&A $3.9M vs $4.8M; cash runway expected into H2 2025.","SNS-101 Phase 1 data at SITC: no cytokine release syndrome, no dose-limiting toxicities, dose-proportional pharmacokinetics.","Enrollment ahead of schedule: 17 patients treated; monotherapy dose escalation at 15 mg/kg; combination arm cleared 3 mg/kg.","Apped Stephanie Krebs as CBO; SNS-201 and SNS-102 lead candidates selected; milestones: combo data Q1 2024, monotherapy topline Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-271921","json":"https://secwatch.observer/filing/0001193125-23-271921.json","markdown":"https://secwatch.observer/filing/0001193125-23-271921.md","text":"https://secwatch.observer/filing/0001193125-23-271921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/0001193125-23-271921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/d908748d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:06:36.923608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15fdb3c5c7872e1af6dcd0076678a63a0accf0b8","claim":"Sensei Biotherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/0001193125-23-271921-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}